Ken Liljegren

Ken Liljegren is a notable inventor based in Værløse, Denmark. He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative drug formulations. With a total of 7 patents to his name, Liljegren's work has had a substantial impact on the industry.

Latest Patents

One of his latest patents focuses on a crystalline base of the well-known antidepressant drug escitalopram. This invention includes orodispersible tablets comprising escitalopram base, which relates to the preparation of purified salts of escitalopram, such as the oxalate. The patent also details a process for creating purified escitalopram free base or salts using the hydrobromide. Additionally, it describes an orodispersible tablet with specific hardness and oral-disintegration time, showcasing his commitment to improving pharmaceutical formulations.

Career Highlights

Ken Liljegren is associated with H. Lundbeck A/S, a prominent company in the pharmaceutical sector. His work at Lundbeck has allowed him to focus on developing innovative solutions for mental health treatments. His expertise in drug formulation and patenting has positioned him as a key player in the industry.

Collaborations

Throughout his career, Liljegren has collaborated with talented individuals such as Troels Volsgaard Christensen and Robert Dancer. These partnerships have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Ken Liljegren's contributions to the pharmaceutical industry through his innovative patents demonstrate his dedication to improving mental health treatments. His work continues to influence the field and pave the way for future advancements.

This text is generated by artificial intelligence and may not be accurate.